CTLA4 and melanoma: Similarly, Ye et al. (2020) demonstrated that a small-molecule MMP-2/MMP-9 inhibitor SB-3CT improved the therapeutic effect of PD-1 or CTLA-4 inhibition in melanoma and lung cancer model.